Review of erlotinib in the treatment of advanced non-small cell lung cancer.
Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung cancer (NSCLC). Once stimulated by ligand, the downstream pathway is activated leading to cell growth, survival, and carcinogenesis. There are several methods of EGFR inhibition including monoclonal antibodies directed against the external region and small molecule inhibitors of TK domain. Erlotinib and gefitinib are orally available small molecule EGFR TK inhibitors, with proven efficacy in NSCLC. The most common side effects are skin toxicity and diarrhea. Erlotinib has been shown to improve survival compared to placebo in second or third-line therapy for NSCLC. However, erlotinib in combination with chemotherapy failed to show a survival advantage in two first-line studies which could be due to the timing of chemotherapy administration. In general, patients with adenocarcinoma histology, female gender, Asian ethnicity, and never smokers have a better response when treated with erlotinib. This could be related to the presence of EGFR mutations, lack of KRAS mutations, or overexpression of EGFR as measured by fluorescent in-situ hybridization (FISH) analysis. Future studies should concentrate on further development of predictors of clinical benefit with erlotinib, overcoming resistance to erlotinib that develops in initial responders, as well as more effective sequencing of erlotinib with chemotherapy and combinations of the drug with other "targeted" therapeutic agents.
Ganjoo
Kristen N
KN
Palo Alto VA Heath Care Systems, Palo Alto, CA, USA;
Wakelee
Heather
H
N Engl J Med. 2005 Jul 14;353(2):123-32
16014882
Cancer Genet Cytogenet. 2007 Mar;173(2):107-13
17321325
J Thorac Oncol. 2009 Jul;4(7):862-8
19494788
Clin Cancer Res. 2006 Jul 1;12(13):3908-14
16818686
Mol Cancer Ther. 2007 Apr;6(4):1223-9
17406029
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
15329413
J Clin Oncol. 2005 Apr 10;23(11):2544-55
15753462
Clin Cancer Res. 2007 Jun 15;13(12):3731-7
17575239
J Clin Oncol. 2008 Feb 20;26(6):863-9
18281658
J Clin Oncol. 2000 Jun;18(12):2354-62
10856094
J Clin Oncol. 2007 Jun 1;25(16):2248-55
17538169
J Clin Oncol. 2009 Feb 1;27(4):591-8
19075278
JAMA. 2003 Oct 22;290(16):2149-58
14570950
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
Semin Oncol. 2002 Feb;29(1 Suppl 4):3-14
11894009
J Clin Oncol. 2004 Apr 1;22(7):1201-8
14993230
J Clin Oncol. 2005 Sep 1;23(25):5900-9
16043828
J Am Acad Dermatol. 2006 Feb;54(2):358-60
16443077
Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4421s-4425s
16857821
Clin Cancer Res. 2006 Jun 15;12(12):3652-6
16778092
J Clin Oncol. 2007 May 20;25(15):1960-6
17452677
Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6
15142631
J Clin Oncol. 2007 Apr 20;25(12):1545-52
17442998
Cancer Res. 2007 May 15;67(10):4665-70
17510392
N Engl J Med. 2002 Jan 10;346(2):92-8
11784875
JAMA. 2004 Jul 28;292(4):470-84
15280345
J Clin Oncol. 2003 Jun 15;21(12):2237-46
12748244
Clin Cancer Res. 2006 Mar 1;12(5):1647-53
16533793
J Clin Oncol. 2005 Sep 1;23(25):5892-9
16043829
J Clin Oncol. 2007 Mar 1;25(7):760-6
17228019
J Natl Cancer Inst. 2007 Jun 6;99(11):838-46
17551144
Cancer Res. 2002 May 1;62(9):2554-60
11980649
Cancer. 2006 Sep 1;107(5):1034-41
16878326
J Clin Oncol. 2001 Jul 1;19(13):3267-79
11432895
J Clin Oncol. 2000 May;18(10):2095-103
10811675
Nat Med. 2001 Mar;7(3):285-7
11231620
J Biol Chem. 1984 Jun 25;259(12):7755-60
6330079
Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
16257339
Oncologist. 2007 Jan;12(1):90-8
17285735
Science. 2004 Jun 4;304(5676):1497-500
15118125
Am J Pathol. 1997 Dec;151(6):1523-30
9403702
Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):42-5
17254038
Ann Oncol. 2007 Apr;18(4):752-60
17317677
Mol Biol Med. 1983 Dec;1(5):511-29
6094961
J Clin Oncol. 2006 Jul 20;24(21):3340-6
16785471
J Clin Oncol. 2005 May 10;23(14):3227-34
15886310
J Clin Oncol. 2004 Aug 15;22(16):3238-47
15310767
Cancer Res. 2007 Jun 15;67(12):5667-72
17575133
N Engl J Med. 2005 Jul 14;353(2):133-44
16014883
Acta Derm Venereol. 2004;84(1):23-6
15040473
Science. 2007 May 18;316(5827):1039-43
17463250
N Engl J Med. 2004 Jul 22;351(4):337-45
15269313
J Clin Oncol. 2004 Mar 1;22(5):777-84
14990632
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Clin Cancer Res. 2001 Oct;7(10):2958-70
11595683
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55
17062680
Annu Rev Biochem. 1999;68:965-1014
10872470
Int J Cancer. 1993 Jan 21;53(2):209-14
8381111
J Clin Oncol. 2006 Aug 20;24(24):3831-7
16921034
J Clin Oncol. 2004 May 1;22(9):1589-97
15117980
J Clin Oncol. 2003 Oct 15;21(20):3798-807
12953099
J Clin Oncol. 2009 May 20;27(15):2523-9
19332730
J Natl Cancer Inst. 2005 May 4;97(9):643-55
15870435